Israel’s BrainStorm reported positive interim results of Phase IIa ALS trials of its “NurOwn” stem cell therapy. 71% of patients were in decline before treatment but after treatment 63% were either stabilized or had improved neurological function.
http://www.brainstorm-cell.com/index.php/news-a-events/302-june-2-2014